Benjamin Looker is CLO at Esperion Therapeutics, Inc. (ESPR). They have made 10 open-market trades across 1 company since 2023, most recently 2026-06-17.
CIK 0001859509
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ESPR | 667,524 | $2.1M |
Shares reported on the most recent Form 4, priced at the 2026-06-18 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ESPR | SELL | 2026-06-17 | 2026-06-18 | $3.16 | $37K | +0.2% | N/A | N/A |
| ESPR | SELL | 2026-03-17 | 2026-03-18 | $2.70 | $31K | +5.2% | -18.6% | +26.2% |
| ESPR | SELL | 2026-01-20 | 2026-01-21 | $2.88 | $5K | +17.4% | +16.8% | -36.1% |
| ESPR | SELL | 2025-12-17 | 2025-12-18 | $3.67 | $24K | -2.1% | -23.5% | -33.7% |
| ESPR | SELL | 2025-10-17 | 2025-10-20 | $2.62 | $3K | +0.7% | -1.1% | +2.5% |
| ESPR | SELL | 2025-09-17 | 2025-09-18 | $2.80 | $18K | -6.4% | -0.4% | +29.0% |
| ESPR | SELL | 2025-07-17 | 2025-07-18 | $1.13 | $1K | +19.5% | +78.0% | +124.6% |
| ESPR | SELL | 2025-06-17 | 2025-06-18 | $1.15 | $7K | -9.1% | +6.4% | +151.8% |
| ESPR | SELL | 2023-04-19 | 2023-04-20 | $1.27 | $2K | +3.9% | +30.7% | +21.3% |
| ESPR | SELL | 2023-01-18 | 2023-01-19 | $7.00 | $44K | -7.2% | -18.4% | -80.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.